Welcome to Shelys Pharmaceuticals, a renowned pharmaceutical company of Sub Saharan Africa. Shelys has humble origins starting as a diminutive family business in 1956 and has, over the years, established itself to be one of the largest pharmaceutical companies in East Africa.
Shelys has its footprints in Tanzania ,Zambia ,Malawi ,DRC, Rwanda , Burundi, Mozambique, Madagascar ,Mauritius, Djibouti ,Uganda and Kenya and is a leader in the script market for crucial therapeutic categories such as cough and cold, anti infectives, nutraceuticals, antimalarials, gastro intestinal, pain management, fever and topical inflammation, disinfectants, cardiovascular and erectile dysfunction.
In 2012, Aspen Pharmacare Holdings Limited (Aspen) acquired the remaining share in Shelys Pharmaceuticals Limited providing for a 100% shareholding.Tanzania-based Shelys and Beta Healthcare based in Kenya, a prominent leader in OTC business in Sub Saharan Africa, are both subsidiaries of Shelys Africa. This alliance provides the foundation of Aspen’s expansion into the East and Central African market and the establishment of an affordable, quality, generics brand presence on the continent.
The African continent offers a promising window of opportunity for pharmaceutical expansion. South African-based Aspen Pharmacare, which has manufacturing facilities valued in excess of R1 billion and which produce approximately 6 billion tablets per annum, is suitably positioned to manufacture and supply product across Africa.
With its South African presence established, Aspen has been actively engaged in securing strategic alliances with international partners, including those based in Africa, in a bid to increase its geographic footprint in this territory.
Aspen’s position in Africa through its relationships with international pharmaceutical companies Gilead Sciences Inc and Tibotec Pharmaceuticals Limited, has positioned the company at the forefront of introducing first world technology to the continent to support the implementation of the latest guidelines and protocols for the treatment of HIV/Aids.
Aspen’s range of anti-retrovirals, which include treatment products such as Viread, Truvada and Presista, has established the Group as a valued contributor in the fight against HIV/Aids on the continent.
Aspen’s strategic approach toward providing meaningful solutions against infectious diseases, as well as securing appropriate international partnerships, has created an opportunity for the Group to create a pharmaceutical legacy across the African continent.